A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

NCT01144624 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Sepsis
Septic Shock

Interventions

DRUG: AZD9773
DRUG: Placebo

Sponsor

AstraZeneca